Testing new antibodies to enhance cancer treatment effectiveness
Official title: In vivo testing of an agonistic anti-GITR mAb that induces cell surface clustering to augment signal transduction and a 2nd Gen bispecific anti-GITR/PD1 Ab derivative for improved anti-tumor activity
Funded at Dana-Farber Cancer Inst · NIH-10784286 · Data updated 2026-11-12
This study is looking at new antibodies that help boost your immune system's response to cancer treatments, especially for those with kidney cancer, by making existing therapies work even better together.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $268,059 |
| NIH project number | 1R21CA286345-01 |
| Project ID | NIH-10784286 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with renal cell carcinoma or other malignancies who have not responded adequately to current immunotherapies.
✕Less likely to help
Patients with early-stage cancers or those who have not yet undergone immunotherapy may not benefit from this research.
What this research studies
This research investigates the use of new therapeutic antibodies that target the GITR receptor to improve the effectiveness of existing cancer immunotherapies, particularly those that inhibit PD1. The approach involves developing antibodies that can cluster on the surface of immune cells, enhancing their activation and response against tumors. By combining these new antibodies with existing treatments, the goal is to create a more robust immune response against various types of cancers, including renal cell carcinoma. Patients may be involved in trials to assess the safety and efficacy of these new treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve patient outcomes and survival rates.
How similar studies have gone: Previous research has shown promise in using similar approaches with other immune pathways, indicating potential for success in this novel application.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Marasco, Wayne a. — Dana-Farber Cancer Inst
- Study coordinator: Marasco, Wayne a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.